---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-034618"
form_type: "8-K"
ticker: "MNPR"
cik: "0001645469"
company_name: "Monopar Therapeutics"
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:25:43.900619+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Monopar Therapeutics Q3 2025 net loss $3.4M; cash $143.7M; NDA for ALXN1840 planned early 2026

## Summary
- Net loss $3.4M ($0.48/sh) vs $1.3M ($0.37/sh) in Q3 2024; no revenue reported.
- Cash, equivalents & investments $143.7M as of Sep 30, 2025; funds expected through Dec 2027.
- NDA submission to FDA for ALXN1840 in Wilson disease targeted for early 2026.
- Raised ~$126.9M gross in public offering; $35M used to repurchase 550,229 shares from Tactic Pharma, net ~$91.9M.
- FDA cleared IND for MNPR-101-Lu therapeutic radiopharmaceutical trial in solid tumors.

## SEC filing metadata
- accession: 0001437749-25-034618
- form_type: 8-K
- ticker: MNPR
- cik: 0001645469
- company_name: Monopar Therapeutics
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645469/000143774925034618/0001437749-25-034618-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645469/000143774925034618/mnpr20251105_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-034618
- JSON: https://secwatch.observer/filing/0001437749-25-034618.json
- Plain text: https://secwatch.observer/filing/0001437749-25-034618.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.